Luye Pharma Group Ltd.: Parkinson Disease trials

The registry lists 14 Parkinson Disease studies with Luye Pharma Group Ltd. as lead sponsor. 2 are open to participants now and 0 have results posted.

Phase 1 13Phase 3 1(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• A Phase 1, MAD Study to Evaluate the Safety, Tolerability and Pharmacokinetics of LY03017Not yet recruitingNCT06980207Phase 1
• Effect of Food and Age on the Pharmacokinetics of LY03017Not yet recruitingNCT06793995Phase 1
• A Study to Evaluate the Pharmacokinetics and Safety of LY03003 in Patients With Advanced-stage PDCompletedNCT04630860Phase 1
• A Clinical Trial to Evaluate the Pharmacodynamics/Pharmacokinetics and Safety of LY03003 in Early PD PatientsCompletedNCT04629404Phase 1
• A Study to Evaluate the Human Tolerance and Pharmacokinetics of LY03003CompletedNCT04627155Phase 1
• to Evaluate the Safety, Tolerability and Pharmacokinetics of Four Formulations of LY03009 in Healthy VolunteersStatus unknownNCT04593511Phase 1
• A Study to Evaluate the Effectiveness and Safety of LY03003 in Patients With Early Primary PDCompletedNCT04571164Phase 3
• A Randomized, Open-Label, Crossover Study to Evaluate the Pharmacokinetic Profiles of Rotigotine After a Single Dose of LY03003 (28 mg) Versus After a Week of Daily NEUPRO® Transdermal Patch (4 mg Every 24 Hours) in Healthy VolunteersCompletedNCT04384666Phase 1
• A Multiple Ascending Dose Study With LY03003 in Patients With Early-stage Parkinson's DiseaseCompletedNCT04045678Phase 1
• A Study of LY03003 in Patients With Early-stage Parkinson's DiseaseCompletedNCT04044547Phase 1
• A Study to Assess Pharmacokinetic Profiles of LY03003 and NeuproCompletedNCT03733561Phase 1
• Pharmacokinetic Study of LY03003 in Patients With Parkinson's DiseaseCompletedNCT03589066Phase 1
• Pharmacokinetic Profile of Neupro Patch Administrated at 2 mg, 4 mg, 6 mg and 8 mg/Day Weekly in Patients With Early-stage Parkinson's DiseaseCompletedNCT02728947Phase 1
• Pharmacokinetics and Safety Study of LY03003 in Patients With Early-stage Parkinson's DiseaseCompletedNCT02055274Phase 1